Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine

Vaccine

Volumn 32, Issue 22, 2014, Pages 2618-2622

  Szu, Shousun C ^a   Lin, Kimi F Y ^a   Hunt, Steven ^a   Chu, Chiayung ^a   Thinh, Nguyen Duc ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Division of Food Safety Department of Agriculture   (Viet Nam)

Author keywords

Phase I pectin based; Plant polysaccharide; Safety immunogenicity; Semi synthetic; Typhoid conjugate vaccine

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G; O ACETYLATED PECTIN CARRIER PROTEIN REPA CONJUGATE VACCINE; PECTIN; POLYSACCHARIDE VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MIDDLE AGED; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TYPHOID FEVER; UNITED STATES; VACCINATION; VACCINATION REACTION; VIET NAM;

PHASE I PECTIN-BASED; PLANT POLYSACCHARIDE; SAFETY IMMUNOGENICITY; SEMI-SYNTHETIC; TYPHOID CONJUGATE VACCINE;

ACETYLATION; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CITRUS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PECTINS; POLYSACCHARIDES, BACTERIAL; RECOMBINANT PROTEINS; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84898540165     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.023     Document Type: Article

References (36)

1. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82:346-353. Available from:. http://www.who.int/rpc/TFDisBurden.pdf.
2. Ochai R.L., Acosia C.J., Danovaro-Holiday M.C., Baiqing D., Bhattachary S.K., Agtini M.D., et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull World Health Organ 2008, 86:260-268. Available from:. http://www.who.int/bulletin/volumes/86/4/06-039818/en/.
3. Parry C.M., Ho V.A., Phuong le T., Bay P.V., Lanh M.N., Tung L.T., et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 2007, 51:819-825.
4. Kelly-Hope L.A., Alonso W.J., Thiem V.D., Anh D.D., Canh do G., Lee H., et al. Geographical distribution and risk factors associated with enteric diseases in Vietnam. Am J Trop Med Hyg 2007, 76:706-712.
5. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B., et al. Typhoid fever in children ages less than 5 years. Lancet 1999, 354:734-737.
6. Brooks W.A., Hossain A., Goswami D., Nahar K., Alam K., Ahmed N., et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005, 11:326-329.
7. Klugman K.P., Gilbertson I.T., Koornhof H.J., Robbins J.B., Schneerson R., Schulz D., et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987, ii:1165-1169.
8. Plotkin S.A., Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Int Med 1995, 155:2293-2299.
9. Requirements for Vi polysaccharide for typhoid. (Requirements for Biological Substances No. 48). WHO Expert Committee on Biologic Standardization; Forty Third Report 1994, World Health Organization, Geneva, Annex 1. WHO Technical Report Series, No. 840:14-33. Available from: http://www.who.int/biologicals/vaccines/typhoid/en/index.html.
10. Khan M.I., Soofi S.B., Ochiai R.L., Habib M.A., Sahito S.M., Nizami S.Q., et al. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012, 30:5389-5395.
11. Moore S.E., Jalil F., Szu S.C., Hahn-Zoric M., Prentice A.M., Hanson L.A. Revaccination does not improve an observed deficit in antibody responses in Pakistani adults born of a lower birth weight. Vaccine 2008, 26:158-165.
12. Kossaczka Z., Lin F.Y., Ho V.A., Thuy N.T., Van Bay P., Thanh T.C., et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999, 67:5806-5810.
13. Lanh M.N., Bay P.V., Ho V.A., Thanh T.C., Lin F-Y.C., Bryla D.A., et al. Persistent efficacy of Vi conjugates against typhoid fever in young children. N Eng J Med 2003, 349:1390-1391.
14. Thiem V.D., Lin F.-Y.C., Canh D.G., Son N.H., Anh D.D., Mao D., et al. The Vi conjugate typhoid vaccine is safe, elicites protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18:730-735.
15. Szu S.C. Development of Vi conjugate-a new generation of typhoid vaccine. Expert Rev Vaccines 2013, 12:1273-1286.
16. Szu S.C., Bystricky S. Physical, chemical, antigenic, and immunologic characterization of polygalacturonan, its derivatives, and Vi antigen from Salmonella Typhi. Methods Enzymol 2003, 363:552-567.
17. Bystricky S., Szu S.C. O-acetylation affects the binding properties of the carboxyl groups on the Vi bacterial polysaccharide. Biophys Chem 1994, 51:1-7.
18. Stone A.L., Szu S.C. Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever. J Clin Microbiol 1988, 26:719-725.
19. Pilnik W., Voragen A.G.J. Pectic substances and other uronides. The biochemistry of fruits and their products 1970, vol. 1:53-87. Academic Press, London.
20. Szu S.C., Bystricky S., Hinojosa-Ahumada M., Egan W., Robbins J.B. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1→4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever. Infect Immun 1994, 62:5545-5549.
21. Kossaczka Z., Bystricky S., Bryla D.A., Shiloach J., Robbins J.B., Szu S.C. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun 1997, 65:2088-2093.
22. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 1949, 180:249-261.
23. Szu S.C., Taylor D.N., Trofa A.C., Clements J.D., Shiloach J., Sadoff J.C., et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994, 62:4440-4444.
24. Chaudhary V.K., Jinno Y., FitzGerald D., Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A 1990, 87:308-312.
25. Bitter T., Muir H.M. A modified uronic acid carbazole reaction. Anal Biochem 1962, 4:330-334.
26. Taylor K.A., Buchanan-smith J.G. A colorimetric method for the quantitation of uronic acids and a specific assay for galacturonic acid. Anal Biochem 1992, 201:190-196.
27. Szu S.C., Hunt S., Xie G., Robbins J.B., Schneerson R., Gupta R.K., et al. A human IgG anti-Vi reference for Salmonella enteric serovar Typhi with weight-based antibody units assigned. Vaccine 2013, 31:1970-1974.
28. Szu S.C., Klugman K., Hunt S. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever - based on the efficacy trial of Vi conjugate in young children. Vaccine 2014, [Epub ahead of print]. 10.1016/j.vaccine.2014.02.050.
29. Konadu E.Y., Lin F.Y., Hó V.A., Thuy V.T., Van Bay F., Thanh T.C., et al. Phase 1 and phase 2 studies of Salmonella enteric serovar Paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 2000, 68:1529-1534.
30. Tacket C.O. Plant-derived vaccines against diarrheal diseases. Vaccine 2005, 23:1866-1869.
31. Rosales-Mendoza S., Govea-Alonso D.O., Monreal-Escalante E., Fragoso G., Sciutto E. Developing plant-based vaccines against neglected tropical diseases: where are we. Vaccine 2012, 31:40-48.
32. Lugade A.A., Kalathil S., Heald J.L., Thanavala Y. Transgenic plant-based oral vaccines. Immunol Invest 2010, 39:468-482.
33. Arntzen C., Plotkin S., Dodet B. Plant-derived vaccines and antibodies: potential and limitations. Vaccine 2005, 23:1753-1756.
34. Wetter M., Kowarik M., Steffen M., Carranza P., Corradin G., Wacker M. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj J 2013, 30:511-522.
35. Toraño G., Toledo M.E., Baly A., Fernandez-Santana V., Rodriguez F., Alvarez Y., et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers. Clin Vaccine Immunol 2006, 13:1052-1056.
36. Pozsgay V., Chu C., Pannell L., Wolfe J., Robbins J.B., Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci U S A 1999, 96:5194-5197.